Lobe Sciences Ltd. is a biopharmaceutical company, which engages in the discovery and development of transformative medicines to treat rare diseases. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2012-06-19. The Company, through its wholly owned subsidiaries, Alera Pharma, Inc. and Altemia, Inc., is advancing the development of a patented drug candidate aimed at treating neurological disorders, with an initial focus on chronic cluster headache (Alera). The firm commercializes Altemia MF, a medical food designed to manage deficiencies commonly found in sickle cell disease. Additionally, through Cynaptec Pharmaceuticals, Inc. (Cynaptec), the Company retains an interest in developing Conjugated Psilocin in neurology and psychiatric indications. Conjugated Psilocin is a patented, oral, stable analog of psilocin, the active metabolite of the prodrug psilocybin, designed to enhance bioavailability and therapeutic efficacy, which has been identified as having therapeutic potential in a variety of neurological conditions.
LOBEF stock price ended at $0.05 on 星期四, after rising 0.00%
On the latest trading day Jan 15, 2026, the stock price of LOBEF rose by 0.00%, climbing from $0.04 to $0.05. During the session, the stock saw a volatility of 50.00%, with prices oscillating between a daily low of $0.04 and a high of $0.06. Notably, trading volume dropped by 80.5K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 250.7K shares were traded, equating to a market value of approximately $13.4M.